Suda Pharmaceuticals Ltd produces and develops pharmaceutical products. The Company offers drugs for the treatment of malaria, migraine, nausea, erectile dyfunction, pulmonary arterial hypertension (PHA), anxiety disorder. Suda Pharmaceuticals serves patients in Australia.

Notice Of 2020 Annual General Meeting

Newsletter October 2020

Appendix 4G and FY20 Corporate Governance Statement 2

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Suda Pharmaceuticals (SUD AU)

Notice Of 2020 Annual General Meeting

Newsletter October 2020

Appendix 4g And Fy20 Corporate Governance Statement 2

Fy20 Annual Report To Shareholders 8

Anagrelide Project Update

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)